Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us



Registration           Hotel           Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
 
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
 
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
 
Poster Session OT1
Poster Session OT2
Poster Session OT3
 
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6
 

Program Schedule   >  Poster Sessions - Poster Discussion 1

Poster Discussion 1 
   
  PI3K/TOR Pathway
PD1-1 PI3-kinase mutations in recurrences in patients with estrogen receptor positive breast cancer
Dixon JM, Renshaw L, Keys J, Sims A, Thomas J, Wilson TR, Lackner MR. Breakthrough Research Unit, Western General Hospital, Edinburgh, United Kingdom; Genentech, Inc., South San Francisco.
PD1-2 PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients
Contreras A, Herrera S, Wang T, Mayer I, Forero A, Nanda R, Goetz M, Chang JC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Osborne CK, Schiff R, Rimawi MF. Baylor College of Medicine, Houston, TX; Vanderbilt University, Nashville, TN; University of Alabama in Birmingham, Birmingham, AL; University of Chicago, Chicago, IL; Mayo Clinic, Rochester, MN; The Methodist Hospital, Houston, TX.
PD1-3 Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer
Juric D, Saura C, Cervantes A, Kurkjian C, Patel MR, Sachdev J, Mayer I, Krop IE, Oliveira M, Sanabria S, Cheeti S, Lin RS, Graham RA, Wilson TR, Parmar H, Hsu JY, Von Hoff DD, Baselga J. Massachusetts General Hospital Cancer Center, Boston, MA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; University of Oklahoma, Oklahoma City, OK; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Virginia G. Piper Cancer Center/TGen, Scottsdale, AZ; Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech, Inc., South San Francisco, CA.
PD1-4 A phase I study of BKM120 and fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer
Ma CX, Wang J, Luo J, Naughton M, Nagaraj G, Bazzell N, Ellis MJ. Washington University School of Medicine, Saint Louis, MO.
PD1-5 Targeting PI3K overcomes in vivo resistance to everolimus in estrogen receptor (ER+) breast cancer
O'Brien NA, Tong L, Ayala R, Issakhanian S, McDonald K, Hurvitz SA, DiTomaso E, Linnartz R, Finn RS, Hirawat S, Slamon DJ. David Geffen School of Medicine at UCLA, Los Angeles, CA; Novartis Pharmaceuticals, Cambridge, MA.
PD1-6 A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC)
Mayer IA, Jovanovic B, Abramson VG, Mayer EL, Sanders ME, Bardia A, Dillon PM, Kuba MG, Carpenter JT, Chang JC, Lehmann BD, Meszoely IM, Grau A, Shyr Y, Arteaga CL, Chen X(S), Pietenpol JA. Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MD; University of Virginia Health Sciences Center, Charlottesville, VA; University of Alabama, Birmingham, AL; Methodist Hospital Research Institute, Houston, TX; Massachusetts General Hospital, Boston, MD.
PD1-7 Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) evaluation in the NeoALTTO trial (BIG 01-06)
Nuciforo P, AURA C, Prudkin L, Jimenez J, MARTINEZ P, Peiro' N, Ellis C, Eidtmann H, Piccart M, Baselga J. Vall d'Hebron Institute of Oncology, Barcelona, Spain; GlaxoSmithKline; University Hospital Kiel, Kiel, Germany; Jules Bordet Institute, Brussels, Belgium; Memorial Sloan Kettering Cancer Center, New York.
PD1-8 Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
Rodrik-Outmezguine V, Yao Z, Berger M, De Stanchina E, Klinowska T, Barratt D, Baselga J, Rosen N. MSKCC, New York, NY; AstraZeneca, Macclesfield, Cheshire, United Kingdom. Vanessa Rodrik-Outmezguine is a recipient of an AACR Scholar-In-Training Award
PD1-9 P-REX1 employs a positive feedback loop to activate growth factor receptor/PI3K signaling
Miller TW, Dillon LM, Bean JR, Yang W, Balko JM, McDonald WH, Friedman DB, Gonzalez-Angulo AM, Mills GB, Arteaga CL. Geisel School of Medicine at Dartmouth, Lebanon, NH; Vanderbilt University School of Medicine, Nashville, TN; Univ. of Texas M.D. Anderson Cancer Center, Houston, TX.
   
 
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
       line
Copyright 2014 SABCS. All rights reserved. - Privacy Policy